Clinical Trial

A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Evaluation of the efficacy of A166 in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-17.
Trial Details
NCT Number NCT07299825
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Her 2 Positive Breast Cancer
Enrollment 40 participants
Start Date 2024-09-20
Primary Completion 2027-09-20 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-08